Analyzing Milestone Pharmaceuticals (NASDAQ:MIST) and Palisade Bio (NASDAQ:PALI)

Palisade Bio (NASDAQ:PALI) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares Palisade Bio and Milestone Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250,000.00	1,401.13	-$16.78 million	($0.48)	-4.19
Milestone Pharmaceuticals	$1.55 million	84.34	-$63.06 million	($0.69)	-1.52

Palisade Bio has higher earnings, but lower revenue than Milestone Pharmaceuticals. Palisade Bio is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Palisade Bio and Milestone Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1	0	7	2	3.00
Milestone Pharmaceuticals	1	1	4	1	2.71

Palisade Bio currently has a consensus target price of $9.00, suggesting a potential upside of 347.76%. Milestone Pharmaceuticals has a consensus target price of $6.40, suggesting a potential upside of 509.52%. Given Milestone Pharmaceuticals’ higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Palisade Bio.

Profitability

This table compares Palisade Bio and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Volatility and Risk

Palisade Bio has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Summary

Palisade Bio beats Milestone Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.